Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan tells Proactive Investors the cell therapy development company has inked a collaboration and licensing deal with ExcellaBio Ltd for exosome-related technologies, in addition to a recent collaboration agreement with Digilab Inc to develop a live cell printing process and systems to automate the production of 3D cell and tissue structures.
Orgenesis CEO talks through most recent collaborations: 3D cell printing and exosome technologies
Quick facts: Orgenesis
Price: 5.4 USD
Market Cap: $87.27 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE